#### **TRAINING UPDATE**

Lab Location: Department:

SGAH and WAH

Date Implemented: Blood Bank

03.06.2015

Due Date:

03.15.2015

#### **DESCRIPTION OF PROCEDURE REVISION**

## Name of procedure:

Quality Variance Form Blood Bank

### **Description of change(s):**

- a. Form updated per discussion during March staff meeting.
- b. SOP updated to reflect changes to form.
- c. SGMC form will be blue while WAH form will be yellow.

### **Electronic Document Control System**



**Document No.:** AG.F15[3]

Title: QUALITY VARIANCE FORM BLOOD BANK

Owner: LESLIE.X.BARRETT LESLIE BARRETT

Status INWORKS

Effective Date: 03-Apr-2015

**Next Review Date:** 

#### Non-Technical SOP

Title	Blood Bank Quality Variance Forms	
Prepared by	Stephanie Codina	Date: 11.28.2011
Owner	Stephanie Codina	Date: 11.28.2011

Laboratory Approval		
Print Name and Title	Signature	Date
Refer to the electronic signature page for approval and approval dates.		
Local Issue Date:	Local Effective Date:	

Review:		
Print Name	Signature	Date

#### **TABLE OF CONTENTS**

1.	PURPOSE	2
	SCOPE	
	RESPONSIBILITY	
	DEFINITIONS	
	PROCEDURE	
	RELATED DOCUMENTS	
	REFERENCES	
8.	REVISION HISTORY	6
	ADDENDA AND APPENDICES	

#### 1. PURPOSE

This procedure describes the process for detecting, investigating, and responding to events that result in deviations from accepted policies, processes, and procedures or failures to meet requirements defined by regulatory requirements.

#### 2. SCOPE

This procedure applies to any deviation from accepted policy, process, procedure or regulatory requirement.

#### 3. RESPONSIBILITY

All blood bank staff members must understand and adhere to this procedure for reporting non-conformances.

#### 4. **DEFINITIONS**

N/A

#### 5. PROCEDURE

**Initial Reporting** 

	Step	Action	
	1	All non-conformances will be reported via the Quality Variance Form. These	
1		include, but are not limited to, deviations from accepted policy, process,	
		procedure, or regulatory requirement.	
ŀ		A. Suspected transfusion reactions will be documented on the Transfusion	
		Reaction Investigation Form per procedure, Transfusion Reaction	
		Investigation.	
		B. Blood product market lookbacks, recalls, and market withdrawals will be	
ı		documented per procedure, Blood Product Lookbacks, Recalls, and	
		Market Withdrawals.	

Step	Action	
2	Obtain a Quality Variance Form and document the following information in the	
	designated spaces:	
	A. Date of occurrence	
	B. Location of occurrence	
	C. Patient's full name, if applicable	
	D. Patient's medical record number, if applicable	
	E. Accession number of test, if applicable	
	F. Test code or name, if applicable	
	G. Patient location	
3	Check the box that describes the non-conformance.	
	A. Patient Identification Error	
	a. Incorrect patient drawn by lab (this refers to a situation in which	
	the incorrect patient was drawn and the blood in the tube matches	
	the name on the tube).	
	b. Incorrect patient drawn by nursing (this refers to a situation in	
	which the incorrect patient was drawn and the blood in the tube	
	matches the name on the tube).	
	c. Patient not banded with blood bank armband	
	d. Armband information incomplete or incorrect	
	e. Blood bank armband removed prematurely	
	f. Patient's current ABO/Rh does not match historical ABO/Rh	
	g. Admitting department error in patient identification or merge	
	h. Wrong blood in tube (this refers to a situation in which the label	
	on the tube does not belong to the same person whose blood is in	
	the tube)	
	B. Ordering	
	a. Test or blood products ordered in incorrect patient (computer	
	entry)	
	b. Blood product requested on incorrect patient (transfusion request)	
F3	c. Incorrect BB number on the request form C. Testing	
	a. Corrected report due to erroneous result	
	b. Clerical/computer data entry error	
	D. Blood Product	
-	a. Incorrect label	
	b. Extended expiration date	
	c. Wasted product	
	E. Specimen	
	a. Not labeled with blood bank labeling system	
	b. Unlabeled	
	c. Double labeled (label beneath blood bank label)	
	d. Mispelled name and/or incorrect MRN	
	e. Label missing one or more required pieces of information (name,	
	MRN, collector's initials, time/date of collection)	
	f. Duplicate specimen	
	g. Specimen collected on patient at incorrect time (T&S drawn when	

Step	Action
14	current T&S in BB, fetal cell screen collected prior to delivery)
	h. Collected in incorrect tube type
	i. Missing specimen
	F. Maintenance and Quality Control
	a. Temperature out of range; no corrective action
	b. Temperature not recorded
	c. QC not documented
	d. QC failure, no corrective action
	G. Issuing
	a. Issued unit did not meet patient's transfusion requirements
	b. Incorrect product issued
	c. Autologous or directed products not issued when available
	d. Product returned outside of acceptable temperature range
	e. ABO confirmation not completed prior to blood product issue H. Procedural error
	a. Failure to follow SOP
	b. Unclear SOP
	c. No procedure available
	d. Tech misunderstood SOP
	I. Supplier error
	a. Manufacturer recall (excludes blood product recalls)
	b. Incorrect or unfilled order
	J. Tech concern (document details on back of form)
	K. Customer complaint (document details on back of form)
	· · · · · · · · · · · · · · · · · · ·
4	Describe the event, applicable details, and immediate corrective actions taken in
	the free-text box on the back of the form if the details are not obvious from the
	description of the variance.
	A. For specimen labeling variances, attach a photocopy of the specimen label
	to the variance form.
	B. For wastage due to nursing errors, attach a photocopy of the "request for
	transfusion form" to the variance form.
5	Determine if the non-conformance is:
	A. An RQI per procedure, Hospital Notification Process for Reportable
	Quality Issues.
	B. An FDA-reportable event per procedure, Biological Product Deviation
	Reporting—FDA Reportable Event.
	Notify a supervisor IMMEDIATELY if the non-conformance is an FDA-reportable event or RQI. Document the notification on the front of the form.

Step	Action	
6	Immediately investigate the incident and take appropriate corrective action.  A. If the non-conformance involves a blood product that has been issued:  a. Attempt to retrieve the blood product prior to transfusion.  b. If transfusion has begun, notify the transfusionist to stop the transfusion immediately if the potential for patient harm exists.  c. Notify the on-call pathologist.  B. Quarantine all blood products with potential non-conformances prior to issue. Refer to procedure, Quarantine of Blood Products.	
7	If notification was made, document the name of the person notified, the date and time of notification, and your tech code in the notification area of the variance form.	
8	Give the Quality Variance Form to a supervisor or place in the designated location.	

Supervi	pervisor's Investigation		
Step	Action		
1	The supervisor will  A. Determine the effect, if any, on the quality of products or services.  B. Evaluate the effect on interrelated activities.  C. Analyze the event to understand root cause (for blood bank errors).  D. Report errors via the hospital incident reporting system when other hospital departments are involved and aid in root cause analysis, if performed.  E. Implement corrective action and discipline, as appropriate.  F. Report to external agencies, when required.  G. Confer with the Blood Bank Medical Director and Quality Assurance department, when applicable.		
2	Documentation of the investigation and corrective action (if implemented) will be documented on the back of the form.		
3	Determine the level of severity.  A. No patient impact  B. Minor impact = redraw/recollection of specimen, treatment delay, rework, patient inconvenience  C. Major impact = Therapy required, increased LOS, change in participation in study, potential for serious injury, or more significant outcome		
4	Completed forms will be forwarded to the Blood Bank Medical Director when the error involves a blood product or blood bank process. The Medical Director will review the non-conformance and approve corrective action by signing the form.		

Step	Action
5	All completed forms will be forwarded to the Quality Assurance department for tracking and trending.

#### 6. RELATED DOCUMENTS

Form: Quality Variance Form (AG.F15) SOP: Transfusion Reaction Investigation

SOP: Blood Product Lookbacks, Recalls, and Market Withdrawals SOP: Biological Product Deviation Reporting—FDA Reportable Event.

SOP: Hospital Notification Process for Reportable Quality Issues

SOP: Quarantine of Blood Products

#### 7. REFERENCES

- a. Fung, M.K., Grossman, B.J., Hillyer, C.D., and Westhoff, C.M. 2014. Technical Manual of the AABB, 18th ed. AABB Publishing, Bethesda, Maryland.
- b. Standards for Blood Banks and Transfusion Services, 29th ed. AABB Publishing, Bethesda, Maryland.

#### 8. REVISION HISTORY

Version	Date	Reason for Revision	Revised By	Approved By
		Supersedes WAH-SGAH B835a.01		
000	3.4.15	Section 5: Updated procedure to reflect changes to form; removed requirement to document whether sample redrawn or corrected report issued; updated levels of severity Section 6: Updated list Footer: Version # leading zero's dropped due to new EDCS in use as of 10/7/13.	SCodina	NCacciabeve

#### 9. ADDENDA AND APPENDICES

None



# **BB Variance Form**

	GEC
	SGMC
П	WAH

Occurr	rence Date:/	/		Occurrence Location:		
Patient	t name:				1	MR#
		(L Name)		(F Name)	— '	
∦ccess	sion #:			Patient location:		
$\supset$						
	Patient Identification		ciaen	t). Check the appropriate box below.  Specimen		Issuing
	Incorrect patient drawn	n by lab		Not labeled with blood bank label		Issued unit did not meet transfusion requirement
	Incorrect patient drawn	n by nursing		Not labeled		Wrong product issued
	Patient not banded with armband	h blood bank		Double labeled (label beneath BB label)		Autologous or directed products not issued when available
	Armband information incorrect	incomplete or		Misspelled name and/or incorrect MRN		Product returned outside of acceptable temperature range
	Blood bank armband re	emoved		Label missing one or more required pieces of information (name, MRN, collector's initials, time or date of collection)		ABO confirmation not completed prior to product issue
	Patient's Current ABO match patient's historic					
	Admitting Department identification or MRN	error in patient		Duplicate specimen		Procedural Error
1	Wrong blood in tube			Specimen collected on patient at incorrect		Failure to follow SOP
1	8		_	time (TS drawn with current TS on file,		Unclear SOP
ט =	Ordering			Fetal Screen collected prior to delivery)	H	No procedure available
h	Test or blood product of	ordered on wrong	П	Collected in wrong tube type	ΠĦ	Tech misunderstood SOP
-	patient (computer entry	()	H	Missing specimen (i.e. cord blood)		Tech misunderstood SOF
	Blood product requeste			whissing specimen (i.e. cord blood)		Supplier Error
>	patient (transfusion req		ĺ	Maintenance/Temperature/QC		
	Incorrect BB number of				+#	Mfg recall (excludes blood products)
	Testing	n request form		Temp out of range; no corrective documentation		Incorrect or unfilled order
					-	
Ц.	Corrected report due to			Temp not recorded	-	Quality Concern / Complaint
	Clerical (computer data	a entry error)		QC not documented		Tech Quality Concern (Document on back
	Blood Product			QC failure, no corrective action	Ш	Customer Complaint (Document on back)
	Incorrect label					
	Extended expiration da	ite				
,	Wasted Product is is an RQI (Se	e reverse), reporte	d to:	Comments (use space on back of this for		RQI#
f thi	is is FDA repo	rtable (See pro	cedur	e), reported to:	_Date:	FDA#
otified:		_ (date/time)		by:	(Tech Code)	
. Su	pervisor Action and	l Recommendatio	n: ( <i>do</i>	ocument all follow-up actions taken on reverse	e) (Tra	ncking) Tech code: No lab involvement (√)
. Le	vel of Severity					140 190 magraement (4)
	☐ No patient im	pact $\square$	Mino	r impact		
. Fol	llow-Up: Hospital I	ncident Report #		Date:		<del></del>
. Sig	gnatures (Sign/Ini	tial and date)				
ıpervi	isor:	Medical Director:		QA Specialist:		Admin, Director:
		•				·



# **BB Variance Form**

	GEC
	SGMC
$\Box$	TA A LI

Laboratory RQI (Reportable Quality Issues)					
Any FDA reportable event					
Any revised result for Blood Bank testing including but not limited to ABO group, Rh type, atypical antibody screen/identification, DAT, RBC antigen typing					
Any Significant Procedural Delay resulting in known or potential impact to patient care (treatment or discharge) including:					
inability to provide timely blood products during an emergent event					
Any Significant Specimen Collection issue (by laboratory staff) causing physical or psychological harm to the patient					
Any issue or event judged by a Pathologist or the CLIA Laboratory Director to have known or potential impact on current patient care					
Rvariation or deviation from the local Hospital Policy and Procedure that has known or potential impact on current patient care.					
To destruction of destruction are lead to lead to lead to lead to the trade to the					
TO DOLL TIPA ALL NICE C					
For RQI or FDA reportable - Notify a Supervisor immediately and document on the front of the form					
se these lines for additional information or to document Tech Quality Concerns:					
E diese lines for additional information of to document from Quality Concerns.					
0					
<u>5</u>					
E//					
7					
ocument: AG. #15[3] Status: INWORKS, Effective: 4/3/2015, JCh					
<del>0</del>					
m Tarangan da kanangan da k					
<u>0</u>					
0					
· · ·					
57					
tat					
ν̃					
R.					
oʻ					
4					
# # # # # # # # # # # # # # # # # # #					
3					
Supervisor Action and Recommendation:					